Company profile
Adicet Bio, Inc.
NASDAQ: ACET · Healthcare · Biotechnology
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 43DQ —GM —SS 56
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$116.8M
Employees
102
as of 2026-08-18
Market cap
$84.6M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$116.8M-$116.8M2025
Operating income-$122.1M-$122.1M2025
Total assets$192.4M$192.4M2025
Liabilities$33.1M$33.1M2025
Equity$159.2M$159.2M2025
Revenue by segment
Filed disclosures · FY2017
By product
Human Health49%
Performance Chemicals26%
Pharmaceutical Ingredients25%
By geography
UNITED STATES76%
GERMANY12%
FRANCE6%
Asia Pacific5%
NETHERLANDS2%
The read
What is Adicet Bio, Inc.’s financial profile?
Adicet Bio, Inc. earned -$116.8M in FY2025 net income.
Peers · Healthcare
NDT Pharmaceuticals Inc.——Aldeyra The——Oncolytics Biotech Inc.——Dogwood Therapeutics, Inc.——Telomir Pharmaceuticals, Inc. Common Stock——RetinalGenix Technologies Inc.——Neighbors
Suffolk →Key facts
CEOChen Schor
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: ACET
Employees102
IPO date2018-01-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.